A-Alpha Bio starts AI antibody data consortium with GSK, Boltz

A-Alpha Bio, a Seattle-based biotech founded by David Younger, has launched a data consortium with GSK and Boltz aimed at improving AI models used for antibody and protein design, according to Endpoints News.

Per the report, Younger’s team has spent months studying how protein-design AI models perform when trained on different kinds and volumes of data. That work underlies the new consortium’s premise, that biopharma’s AI engines require more, and better, data to improve, and that Younger sees a business opportunity in supplying such data to companies developing these models.

GSK, the pharmaceutical major, and Boltz, an AI modeling outfit, join A-Alpha Bio as founding partners in the effort. Endpoints News did not detail, in the material reviewed, the specific financial terms, data-sharing mechanics, or timeline for the consortium’s work.

The formation of the consortium reflects a broader pattern in biopharma, where AI-driven drug design tools are increasingly dependent on the quality and scale of training data, particularly for complex tasks like antibody engineering. A-Alpha Bio’s role, as described in the report, centers on the data science underlying protein design models, developed through its prior research into how such models respond to different training inputs.

No additional companies or research institutions were named as consortium members in the material reviewed.